Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Mergers and Inquisitions

NOVEMBER 1, 2023

Areas like healthcare services and medical devices are fairly generalist and follow standard accounting and valuation. So, it’s not like real estate , oil & gas , or financial institutions , where you must learn a new set of jargon and accounting rules to have a good shot. For healthcare, most of the risks are regulatory.

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

M&A Leadership Council

JUNE 12, 2023

We also recommend you do a dark web search for target company credentials, usernames, passwords, personal information, confidential documents, customer information, account numbers, and social security numbers, to name a few. We also believe it is vital to engage third parties to obtain a security risk assessment.

IT 52

IT M&A Securities Insurance 52

M&A Leadership Council

SEPTEMBER 9, 2021

We also recommend you do a dark web search for target company credentials, usernames, passwords, personal information, confidential documents, customer information, account numbers, and social security numbers, to name a few. We also believe it is vital to engage third parties to obtain a security risk assessment.

IT 52

IT M&A Securities Insurance 52

Cooley M&A

JANUARY 22, 2021

The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion. While deal value was down for the year, deal volume was relatively stable (down only 2.0%

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years. time highs in 2021.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40